Navigation
banner

ImmunoTX Summit

2017-10-232017-10-312017-09-30
EARLY BIRD DISCOUNT! Register by Oct 31, 2017 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Scott Durum

Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
 
About Speaker:

Scott Durum trained in immunology at Wake Forest, Oak Ridge, National Jewish and Yale before coming to the National Cancer Institute, National Institutes of Health. His lab has been interested in the IL-7 pathway for a number of years. Recently, together with collaborators, they found that this is a major pathway driving Acute Lymphoblastic Leukemia, the most common cancer in children. They are working to develop therapeutics directed against the IL-7 pathway in this disease.

Gordon Freeman

Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
 
About Speaker:

Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School.  Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University.  His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).

In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction.  He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack.  He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and 2017 Warren Alpert Foundation award for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.

Michael Karin

Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
 
About Speaker:

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and develops as a result of chronic liver injury and inflammation. The major causes of chronic liver injury are hepatitis B and C virus infections, but in the US and Europe their pathogenic importance has been eclipsed by non-alcoholic (NASH) and alcoholic (ASH) steatohepatitis. Using a novel mouse model developed in our lab, we have shown that NASH pathogenesis and HCC development depend on endoplasmic reticulum (ER) stress, elevated de novo lipogenesis, ballooning degeneration of hepatocytes, induction of TNF expression and hepatic accumulation of p62. NASH and ASH are also associated with upregulation of immunoglobulin A (IgA), first identified in human patients and confirmed in our mouse model. We found that in both human and mouse livers, elevation of circulating IgA is due to accumulation of IgA-producing plasmablasts and plasma cells. These IgA-producing cells express high amounts of PD-ligand 1 (PD-L1) and IL-10 and possess the ability to inhibit activation of HCC-directed cytotoxic CD8+ T lymphocytes (CTL). The inhibition of CTL activation prevents liver protective immunosurveillance, thereby resulting in growth and malignant progression of neoplastic nodules that develop as a result of chronic liver inflammation. Importantly, depletion or ablation of liver IgA-producing cells results in re-invigoration of HCC-directed CTLs, thereby leading to tumor regression. Thus, treatments that inhibit accumulation of liver IgA-producing cells should be effective in preventing progression from NASH and ASH to HCC and inducing regression of established tumors.

Jennifer Towne

Jennifer Towne
Senior Scientific Director
Janssen
Jennifer Towne
Senior Scientific Director
Janssen
 
About Speaker:
Cytokines & Inflammation
DISTINGUISHED SPEAKERS
Rachel Caspi

Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
 
About Speaker:

Dr. Caspi is is a tenured senior investigator, Section Head and Deputy Chief of the Laboratory of Immunology, National Eye Institute, NIH. She also holds an Adjunct Professorship at the University of Pennsylvannia Sch. Med. Dr. Caspi's research centers on immunology of the eye. A major direction is tolerance and autoimmunity to immunologically privileged retinal antigens in animal models of autoimmune uveitis, a potentially blinding human disease. She developed the mouse model of uveitis, now in use worldwide. Her studies have elucidated many basic mechanisms of pathogenesis and helped to devise clinically relevant immunotherapeutic approaches. Her recent work emphasizes the effects of the commensal microbiome on anti-retinal autoimmunity as well as on mucosal immunity and host defense at the ocular surface. She serves on journal Editorial Boards and is an organizer of ocular and general immunology conferences. Dr. Caspi is the recipient of the highly prestigious Friedenwald award and the Alcon Research Institute award, and has authored and co-authored over 230 publications. http://www.nei.nih.gov/intramural/imm-reg.asp

Manoj Dadlani

Manoj Dadlani
Chief Executive Officer
CosmosID
Manoj Dadlani
Chief Executive Officer
CosmosID
 
About Speaker:
Michael Howell

Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
 
About Speaker:

Michael Howell currently works as the Senior Director of Translational Research at the Incyte Corporation with a focus on immunological diseases. Dr. Howell received his PhD in Immunology from the West Virginia University School of Medicine and then moved onto National Jewish Medical and Research Center where he transitioned from a post doctoral fellow to Assistant Professor in the Division of Allergy and Immunology. While at NJMRC, he served as a Co-Investigator for the Atopic Dermatitis Vaccinia Network and made seminal discoveries in the role of Th2 cytokines on the barrier and innate immune responses of atopic dermatitis patients. Since transitioning to industry, Dr. Howell has held positions at Boehringer Ingelheim, the Immune Tolerance Network, MedImmune, and Incyte. Throughout his career, Dr. Howell has combined clinical and basic science approaches to evaluate inflammatory diseases. This research has been highlighted in national and international meetings, peer-reviewed publications and reviews on immunologic mechanisms and has led to recent patent applications for therapeutic interventions and biomarker strategies in inflammatory diseases.

Alison Humbles

Alison Humbles
Principal Scientist
MedImmune
Alison Humbles
Principal Scientist
MedImmune
 
About Speaker:
Ignacio Juncadella

Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
 
About Speaker:
Dermot McGovern

Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA Scool of Medicine
Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA Scool of Medicine
 
About Speaker:
Laurence Morel

Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
 
About Speaker:

Laurence Morel obtained her PhD from the University of Aix-Marseille (France). She trained as a postdoctoral fellow with Dr. Ward Wakeland at the University of Florida (USA) in immunogenetics, where she started to work on the genetic basis of lupus in mouse models. She was appointed with a faculty position in the department of Pathology, Immunology, and Laboratory Medicine at UF in 1999, where she is currently a tenured professor and the Vice Chair for Research and Academic Affairs. Her research focuses on the mechanisms of lupus pathogenesis using mouse models as well as patients’ samples. In addition to genetic studies, her studies now extend to immune metabolism, the role of the microbiome, and the contribution of mesenchymal stem cells to lupus pathogenesis. Her long-term goal is to identify genes and pathways responsible for lupus susceptibility, to characterize their contribution to autoimmune immunopathology, and to translate these findings into therapeutic targets.

Cathryn Nagler

Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
 
About Speaker:

Cathryn Nagler graduated with honors from Barnard College, Columbia University. She obtained her Ph.D. from the Sackler Institute of Biomedical Science at N.Y.U. School of Medicine and did a postdoctoral fellowship at M.I.T. She was Associate Professor of Pediatrics (Immunology) at Harvard Medical School prior to joining the University of Chicago in 2009. She received the inaugural Bunning Food Allergy Professorship in 2011. Dr. Nagler has participated in numerous review panels for the Crohn’s and Colitis Foundation of America, NIDDK, NIAID, and Food Allergy Research and Education (FARE). She recently began her second term on FARE’s research advisory board. She has served the American Association of Immunologists (AAI) as Section Editor for the Journal of Immunology, Instructor (Mucosal Immunology) for the Introduction to Immunology course and as member of the Program, Clinical Immunology, Publications and Awards Committees. She is the senior editor for Clinical and Translational Immunology for the AAI’s new journal ImmunoHorizons. She has also served as an elected Councilor of the Society for Mucosal Immunology and is an Associate Editor of the journal Mucosal Immunology. Dr. Nagler has a long-standing interest in the mechanisms governing tolerance to dietary antigens and the potential immunomodulatory features of the oral route of antigen administration. Her most recent work examines how commensal bacteria regulate susceptibility to allergic responses to food. She has applied insights gained from studying pre-clinical gnotobiotic murine models of cow’s milk allergy to launch a new company, ClostraBio, which is developing microbiome-modulating therapeutics for the prevention and treatment of food allergy.

Take Ogawa

Take Ogawa
Director, Business Development
Second Genome
Take Ogawa
Director, Business Development
Second Genome
 
About Speaker:
Stanley Perlman

Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
 
About Speaker:

Dr. Perlman currently investigates the pathogenesis of coronavirus-mediated severe human respiratory disease (severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) and of coronavirus-induced demyelination. His laboratory also has a strong interest in the regulatory T cells in the context of infection. He has developed severe animal models for the study of MERS and has also investigated T cell responses in MERS survivors. Prior to joining the faculty of the University of Iowa in 1983, he obtained his Ph.D. at M.I.T. and his M.D. at the University of Miami.

Thomas Schall

Thomas Schall
President and Chief Executive Officer
ChemoCentryx
Thomas Schall
President and Chief Executive Officer
ChemoCentryx
 
About Speaker:
Immunotherapeutics & Immunomonitoring
DISTINGUISHED SPEAKERS
Brian Champion

Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
 
About Speaker:

Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, tumor-specific immunogene therapies for the treatment of cancer.   He was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California, leading the immunology team providing expertise and immunoassays for Pfizer vaccine projects, program leader for an anti-IgE therapeutic vaccine for allergy/asthma, and a member of the leadership team. Prior to this he was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex in Cambridge (UK) developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.

Michael Gresser

Michael Gresser
Chief Scientific Officer
Immungene
Michael Gresser
Chief Scientific Officer
Immungene
 
About Speaker:

Mike Gresser, Ph.D. is Chief Scientific Officer for ImmuneGene. From 2000-2006, Dr. Gresser served as Vice President, Research for Inflammation at Amgen, Inc. Prior to Amgen, he was at the Merck Frosst Center for Therapeutic Research where he rose to be Executive Director of Biochemistry and Molecular Biology. He received his Ph.D in Biochemistry from Brandeis University and did postdoctoral studies at UCLA. Before joining Merck Frosst in 1988 he was Pr ofessor of Chemistry at Simon Frazer University in Burnaby, British Columbia.

Karin Jooss

Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone
Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone
 
About Speaker:
Joost Oppenheim

Joost Oppenheim
Senior Investigator
NIH NCI
Joost Oppenheim
Senior Investigator
NIH NCI
 
About Speaker:

Dr. Oppenheim pioneered the development of cytokine, chemokine and alarmin fields of research. He is currently studying the role of alarmins that activate toll-like receptors, in inducing immunity to cancer. He has been engaged in translational studies aimed at utilizing alarmins as adjuvants in vaccines for use against infectious agents and tumors. He is also investigating means of blocking the immunosuppressive limb of immunity as exerted by T regulatory cells to augment antitumor immunity. Dr. Oppenheim is the Chief of the Laboratory of Molecular Immunoregulation and the Deputy Director of the Cancer and Inflammation Program at the National Cancer Institute which focuses on the effects of inflammation and the immune response on cancer.

Alexander Rakhmilevich

Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
 
About Speaker:

Dr. Rakhmilevich is a distinguished scientist at the University of W isconsin-Madison. He obtained his MD and PhD degrees in Soviet Union. He has been working in the field of cancer immunology since 1985. His current laboratory research involves the develop ment of cancer immunotherapies using activation of macrophages via CD40 ligation

Blythe Sather

Blythe Sather
Senior Research Scientist
Juno Therapeutics
Blythe Sather
Senior Research Scientist
Juno Therapeutics
 
About Speaker:
Peggy Scherle

Peggy Scherle
Group Vice President of Discovery
Incyte
Peggy Scherle
Group Vice President of Discovery
Incyte
 
About Speaker:
Steffen Walter

Steffen Walter
Chief Scientific Officer
Immatics
Steffen Walter
Chief Scientific Officer
Immatics
 
About Speaker:

Dr Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology. For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities. In 2015, Dr Walter co-founded Immatics US, Inc. in Houston, Texas as a joint venture between Immatics and MD Anderson Cancer Center (MDACC) to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. As CSO, at Immatics US he leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs. Dr Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Brain and Blood. Dr Walter gained his PhD in Immunology from the University of Tuebingen, Germany.

Immunogenicity & Immunotoxicity
DISTINGUISHED SPEAKERS
Annie De Groot

Annie De Groot
Founder, CEO & CSO
Epivax, Inc.
Annie De Groot
Founder, CEO & CSO
Epivax, Inc.
 
About Speaker:

Annie De Groot is a Smith College graduate (Class of 1978) and medical doctor trained at the University of Chicago (Pritzker School of Medicine, 1983). She trained in Internal Medicine and Infectious Disease at New England Medical Center, and was a research fellow at the NIH (1986-1989). She has both laboratory bench (NIH) and field (former Zaire, the Gambia, and Mali) experience in vaccine research and vaccination campaigns. Having experienced both the beauty of discovery in bench research and the thrill of improving patient lives in her field and clinical work, she has worked to expand the engagement of bench scientists in clinical work and vice versa, whenever possible.

Following her Infectious Disease Fellowship (NEMC), she became a faculty member at Brown University in 1993, where she began to develop the cutting edge computational vaccine design tools for which she is well known. She licensed the first versions of these tools to EpiVax, Inc. in 1998, formed the company with two partners, and has served as CEO/CSO and President of the company since its inception. With Bill Martin cofounder, she has succeeded in establishing EpiVax as a leading company in the field of immunoinformatics, working with a range of global clients and partners to improve the design of vaccines and biologics and improving human health everywhere.

De Groot moved her academic affiliation from Brown University to University of Rhode Island in 2009. De Groot became Director of the Institute for Immunology and Informatics and was subsequently awarded $13M in funding from the NIH to develop the ‘iCubed’ as a center of excellence in Computational Vaccinology. She is the author more than 190 peer-reviewed publications in the fields of computational vaccinology, biodefense, personalized vaccines, and immunology.

Since 2016, she and her business partner Bill Martin have been working to establish a new subsidiary of EpiVax, tentatively called Ancer, that will focus on the emerging field of immune-oncology. Ancer will develop personalized cancer vaccines based on the patients’ own tumor genome. Should De Groot succeed in translating these concepts to the clinic, she will have realized her lifelong dream, which is to make vaccines that are tailored to the individual, highly efficient, safe, and accessible worldwide. She has won numerous awards, including the Smith Medal in 2013, was recognized as one of the 50 most influential people in vaccinology in 2014 and named Vaccine company CEO of the year in 2016.

Kei Kishimoto

Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
 
About Speaker:

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines b ased on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provid ed the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto receive d his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Eszter Lazar-Molnar

Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
 
About Speaker:

Dr. Lazar-Molnar is an assistant professor in the Department of Pathology at the University of Utah School of Medicine. She received her PhD in biological sciences at the Semmelweis University in Budapest, Hungary and completed a postdoctoral fellowship in the laboratory of Dr. Stanley G. Nathenson at the Albert Einstein College of Medicine in Bronx, New York, where she was studying immune regulation through costimulatory molecules and finding new ways for designing immunotherapy. She was the recipient of a Cancer Research Institute postdoctoral fellowship and the Belfer Outstanding Postdoctoral Research Award in 2009. She completed a clinical immunology fellowship at the University of Utah and is currently a medical director in Immunology at ARUP and assistant director of the Histocompatibility & Immunogenetics Laboratory at the University of Utah. Her research interests include cellular immunology, immunotherapy, and transplantation immunology. Dr. Lazar-Molnar is board certified by the American Board of Medical Laboratory Immunology (ABMLI) and American Board of Histocompatibility and Immunologenetics (ABHI).

Hong-Gee Lee

Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
 
About Speaker:
Meina Liang

Meina Liang
Director, Clinical Pharmacology and DMPK
MedImmune
Meina Liang
Director, Clinical Pharmacology and DMPK
MedImmune
 
About Speaker:
Kingston HG Mills

Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
 
About Speaker:
David W. Scott

David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
 
About Speaker:

David W. Scott, Ph.D. is Vice Chair for Research, Department of Medicine, Uniformed Services School of Health Sciences, Bethesda, MD. An alumnus of Antioch College, University of Chicago (MS) and Yale (PhD). Following a fellowship at Oxford University, he held tenured positions at Duke University, University of Rochester, and University of Maryland Medical School. Dr. Scott has contributed to over 200 research papers on immunologic tolerance, and its application in autoimmune diseases, hemophilia and gene therapy. The author of two textbooks, including The Nature of Immunologic Tolerance, he ia recipient of a number of awards, e.g. Distinguished Service Award from the American Association of Immunologists, a Boarhaave Professorship at Leiden University in Holland, and the 2009 Scientific Achievement Award from AAPS.

Albert J Wong

Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
 
About Speaker:

Dr. Wong received his M.D. from the Johns Hopkins School of Medicine. He did a postdoctoral fellowship at the Hopkins Oncology Center under Dr. Bert Vogelstein and then held faculty positions at the Fox Chase Cancer Center and the Thomas Jefferson University before joining the Cancer Biology Program and the Dept. of Neurosurgery at Stanford University in 2005. Focusing on the causes and immunotherapy of human brain tumors, Dr. Wong has made several key discoveries, including the identification of the EGFRvIII alteration and the Gab1 signaling molecule. He showed that EGFRvIII can be used as a vaccine to treat brain tumors, which has led to several clinical trials. This led him to found the biotech company Alteris Therapeutics and as its President led its successful acquisition by Celldex Therapeutics. He has served on numerous review committees for the NIH and ACS, has been an advisor to several universities and pharmaceutical companies, and has been recognized with several honors, including Who’s Who in America, and finalist for regional Biotech Company of the Year.